MedPath

side-effect profile and outcome of patients receiving four drug ATT sequentially compared to standard four drug ATTâ?? in patients with tubercular meningitis

Phase 4
Conditions
Health Condition 1: null- patients with Tubercular meningitis.No history of HepatitisA,B,C,E,CLD,HIV,alcoholism,hepatotoxic drugs,CRF, hepatic failure and contra-indications to ATT,Pregnant and lactating women.
Registration Number
CTRI/2017/10/010072
Lead Sponsor
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients with fever and altered sensorium for 10 days or more.

Diagnosed as Definite and probable tubercular meningitis diagnosed on the basis of clinical, CSF and radiological criteria.

Presence of AFB in CSF smear or culture, positive PCR for M. tuberculosis in CSF will be considered definitive evidence of TBM.

Exclusion Criteria

Pregnant and lactating women.

Serological evidence of Hepatitis A, B, C, E.

Ultra-sonographic (USG) evidence of chronic liver disease (CLD) or gall bladder disease.

HIV infection.

long term alcoholism (defined as consumption of 148 g of alcohol per day for at least 1 year).

concomitant consumption of other potentially

hepatotoxic drugs (eg, methotrexate, phenytoin, valproate, and fluconazole.

Failure to give written informed consent.

Chronic renal failure

Hepatic failure.

Heart failure.

Carcinomatous meningitis.

Contra-indications to ATT, steroids or aspirin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Occurrence and predictors of DIH defined using the criteria stated above.Timepoint: 6 months
Secondary Outcome Measures
NameTimeMethod
Disability at discharge, 3 and 6 months based on modified Barthel index and m RS score. <br/ ><br>Mortality at 28 days, 3 months and 6 months. <br/ ><br>Residual deficits in terms of seizures, cognitive, cranial nerve and motor deficits at the end of 6 months. <br/ ><br>Timepoint: 6 months
© Copyright 2025. All Rights Reserved by MedPath